T. Rowe Price Associates
BIOA

T. Rowe Price Associates’s BioAge Labs BIOA Stock Holding History

T. Rowe Price Associates’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$717K Buy
29,247
+7,829
+37% +$141K ﹤0.01% 2461
2026
Q1 		$375K Buy
21,418
+6,610
+45% +$127K ﹤0.01% 2568
2025
Q4 		$196K Buy
14,808
+2,917
+25% +$25.9K ﹤0.01% 2817
2025
Q3 		$70K Buy
+11,891
New +$55.7K ﹤0.01% 2978
2024
Q4 		– Sell
-449,837
Closed -$9.36M – 3066
2024
Q3 		$9.36M Buy
+449,837
New +$9.01M ﹤0.01% 1148

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

T. Rowe Price Associates's BIOA Position: Q2 2026 in Review

T. Rowe Price Associates increased its BioAge Labs (BIOA) stake by 37% in Q2 2026, buying an estimated $141K and bringing the position to 29,247 shares worth $717K. The position accounts for ﹤0.01% of the portfolio, ranked #2461.

T. Rowe Price Associates first reported a position in BIOA in Q3 2024 and has held it in 5 quarters since. The position peaked at $9.36M in Q3 2024. 150 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • T. Rowe Price Associates held 29,247 shares of BioAge Labs worth $717K as of Q2 2026.
  • T. Rowe Price Associates bought 7,829 BioAge Labs shares in Q2 2026, an estimated $141K.
  • BioAge Labs made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2461 holding.
  • T. Rowe Price Associates first reported a position in BioAge Labs in Q3 2024 and has held it in 5 quarters since.
  • T. Rowe Price Associates's BioAge Labs position peaked at $9.36M in Q3 2024.
  • 150 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.